The<unk>  is generally safe with no increased risk of serious adverse effects.<unk> s are approved for use in over 100 countries, with more than 100 million doses distributed worldwide. Extensive clinical trial and post-marketing safety surveillance data indicate that both Gardasil and Cervarix are well tolerated and safe. When comparing the<unk>  to a placebo (control) vaccine taken by women, there is no difference in the risk of severe adverse events. Gardasil is a 3-dose (injection) vaccine. , there were more than 57 million doses distributed in the United States, though it is unknown how many were administered. There have been 22,000 Vaccine Adverse Event Reporting System (VAERS) reports following the vaccination. Ninety-two percent were reports of events considered to be non-serious (e.g., fainting, pain and swelling at the injection site (arm), headache, nausea and fever), and the rest were considered to be serious (death, permanent disability, life-threatening illness and hospitalization). However, VAERS reports include any reported effects whether coincidental or causal. In response to concerns regarding the rates of adverse events associated with the vaccine, the CDC stated: "When evaluating data from VAERS, it is important to note that for any reported event, no cause-and-effect relationship has been established. VAERS receives reports on all potential associations between vaccines and adverse events." , there were 44 U.S. reports of death in females after receiving the vaccine. None of the 27 confirmed deaths of women and girls who had taken the vaccine were linked to the vaccine. There is no evidence suggesting that Gardasil causes or raises the risk of Guillain–Barré syndrome. Additionally, there have been rare reports of blood clots forming in the heart, lungs, and legs. A 2015 review conducted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee concluded that evidence does not support the idea that<unk> tion causes complex regional pain syndrome or postural orthostatic tachycardia syndrome. , the CDC continued to recommend Gardasil vaccination for the prevention of four types of<unk> . The manufacturer of Gardasil, has committed to ongoing research assessing the vaccine's safety. According to the Centers for Disease Control and Prevention (CDC) and the FDA, the rate of adverse side effects related to Gardasil immunization in the safety review was consistent with what has been seen in the safety studies carried out before the vaccine was approved and were similar to those seen with other vaccines. However, a higher proportion of syncope (fainting) was seen with Gardasil than is usually seen with other vaccines. The FDA and CDC have reminded health care providers that, to prevent falls and injuries, all vaccine recipients should remain seated or lying down and be closely observed for 15 minutes after vaccination. The<unk> tion does not appear to reduce the willingness of women to undergo pap tests. Contraindications While the use of<unk> s can help reduce cervical cancer deaths by two thirds around the world, not everyone is eligible for vaccination. There are some factors that exclude people from receiving<unk> s. These factors include: * People with history of immediate hypersensitivity to vaccine components. Patients with a hypersensitivity to yeast should not receive Gardasil since yeast is used in its production. * People with moderate or severe acute illnesses. This does not completely exclude patients from vaccination, but postpones the time of vaccination until the illness has improved. Pregnancy In the Gardasil clinical trials, 1,115 pregnant women received the<unk> . Overall, the proportions of pregnancies with an adverse outcome were comparable in subjects who received Gardasil and subjects who received placebo. However, the clinical trials had a relatively small sample size. , the vaccine is not recommended for pregnant women. The FDA has classified the<unk>  as a pregnancy Category B, meaning there is no apparent harm to the fetus in animal studies.<unk> s have not been causally related with adverse pregnancy outcomes or adverse effects on the fetus. However, data on vaccination during pregnancy is very limited and vaccination during the pregnancy term should be delayed until more information is available. If a woman is found to be pregnant during the three-dose series of vaccination, the series should be postponed until pregnancy has been completed. While there is no indication for intervention for vaccine dosages administered during pregnancy, patients and health-care providers are encouraged to report exposure to vaccines to the appropriate<unk>  pregnancy registry.
HPV vaccine
Pap test
Cervical screening
Anal Pap smear
Polio vaccine
BCG vaccine
Hepatitis B vaccine
MMR vaccine